Your session is about to expire
← Back to Search
Anti-fibrinolytic agent
Nebulized Tranexamic Acid for Hemorrhage (TEAPOT Trial)
Phase < 1
Waitlist Available
Led By Andrew D Meyer, MD, MS
Research Sponsored by The University of Texas Health Science Center at San Antonio
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
1. Received a tonsillectomy
2. Presents to the ED with secondary\* post-tonsillectomy hemorrhage
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 18 months (or duration of study)
Awards & highlights
Summary
After a child has their tonsils removed, sometimes they might bleed which can be a problem. There is a special mist medicine called nebulized tranexamic acid (TXA) that might help stop the bleeding without having to touch the sore spot. If this mist works well, it could help kids get better by making sure they don't have to go back for more surgery or need blood from someone else. Not having another surgery is good because it means kids won't have to sleep under medicine again, which can sometimes be risky for their brains and breathing, and they won't feel as scared or hurt.
Who is the study for?
This trial is for children who have had their tonsils removed and are experiencing bleeding afterwards. It's important that they haven't had any reactions to tranexamic acid before, and they aren't currently taking medication that affects blood clotting.
What is being tested?
The study is testing a mist medicine called nebulized tranexamic acid (TXA) against normal saline to see if TXA can stop post-operative bleeding in kids without additional surgery or the need for blood transfusions.
What are the potential side effects?
Tranexamic acid may cause side effects like headaches, muscle cramps, or an upset stomach. In rare cases, it could cause more serious problems like blood clots or allergic reactions.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline to 18 months (or duration of study)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 18 months (or duration of study)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Indirect local concentration of nebulized TXA
Number of nebulizations per patient
Number of patients enrolled per month
+1 moreSecondary study objectives
Estimated blood loss
Number of blood transfusions required
Number of recurrences of PTH
+1 moreOther study objectives
State-Trait Anxiety Inventory (STAI) for Adults
State-Trait Anxiety Inventory for Children (STAIC)
Wong-Baker FACES Pain Rating Scale
Side effects data
From 2017 Phase 4 trial • 246 Patients • NCT020308217%
Deep Infection
4%
Superficial Cellulitis
2%
Hematoma/Seroma
100%
80%
60%
40%
20%
0%
Study treatment Arm
Tranexamic Acid (TXA) - Total Hip Arthroplasty
Epsilon-aminocaproic Acid (Amicar) - Total Hip Arthroplasty
Epsilon-aminocaproic Acid (Amicar) - Total Knee Arthroplasty
Tranexamic Acid (TXA) - Total Knee Arthroplasty
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Nebulized Tranexamic AcidExperimental Treatment1 Intervention
Subjects will be adminstered nebulized TXA post-tonsillectomy if they return to the emergency room with hemorrhage after surgery
Group II: Nebulized SalinePlacebo Group1 Intervention
Subjects will be adminstered nebulized saline post-tonsillectomy if they return to the emergency room with hemorrhage after surgery
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tranexamic Acid Injectable Product
2020
Completed Phase 4
~430
Find a Location
Who is running the clinical trial?
The University of Texas Health Science Center at San AntonioLead Sponsor
458 Previous Clinical Trials
91,601 Total Patients Enrolled
5 Trials studying Hemorrhage
7,546 Patients Enrolled for Hemorrhage
Andrew D Meyer, MD, MSPrincipal InvestigatorThe University of Texas Health Science Center at San Antonio
Share this study with friends
Copy Link
Messenger